Insider · CIK 0001639386
Alan D. Sobel
Files at CTSO (Cytosorbents Corp). First filing Dec 15, 2023, latest Sep 16, 2026.
In brief
Alan D. Sobel files SEC Form 4 as director at CTSO (Cytosorbents Corp). Since Dec 15, 2023, Alan D. Sobel has reported 2 open-market buys worth $45k and 0 open-market sells worth $0, the latest filed on Sep 16, 2026.
A track record needs three past buys with six months of prices behind them; Alan D. Sobel has 0, so none is measured yet.
The newest scored trade: bought $15k of CTSO on Sep 15, 2026, filed Sep 16, 2026, scored 36 (weak). In the last 12 months: 1 buy worth $15k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CTSO: Cytosorbents Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Cytosorbents Corp | $15k 2,500 shares | +34% | - | |
| 49Moderate | Cytosorbents Corp | $30k 22,557 shares | +28% | +70% from low-58% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +1,900 | $6.12 | $12k | 9,287 | 28 d ago |
| Sep 15, 2026 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +500 | $6.05 | $3,025 | 9,787 | 28 d ago |
| Sep 15, 2026 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +100 | $6.01 | $601 | 9,887 | 28 d ago |
| Aug 8, 2025 | CTSO Cytosorbents Corp | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Aug 8, 2025 |
| Feb 24, 2025 | CTSO Cytosorbents Corp | OOut-of-the-money exercise Common Stock | +21,950 | $1.13 | $25k | 145,757 | Feb 26, 2025 |
| Feb 24, 2025 | CTSO Cytosorbents Corp | OOut-of-the-money exercise Series A Right Warrants (right to buy)derivative | -21,950 | $1.13 | $25k | 0 | Feb 26, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | XIn-the-money exercise Common Stock | +21,950 | $1.00 | $22k | 123,807 | Jan 22, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | XIn-the-money exercise Subscription Rights (right to buy)derivative | -21,950 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | JOther Series A Right Warrantsderivative | +21,950 | - | - | 21,950 | Jan 22, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | JOther Series B Right Warrantsderivative | +21,950 | - | - | 21,950 | Jan 22, 2025 |
| Apr 2, 2024 | CTSO Cytosorbents Corp | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | - | - | 22,000 | Apr 4, 2024 |
| Dec 13, 2023 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +22,557 | $1.33 | $30k | 101,857 | Dec 15, 2023 |
| Dec 13, 2023 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock Warrant (Right to Buy)derivative | +7,894 | - | - | 7,894 | Dec 15, 2023 |
Questions about Alan D. Sobel
Answered from the filings on this page, as of the latest one.
Is Alan D. Sobel buying or selling?
In the last 12 months Alan D. Sobel reported 1 open-market buy worth $15k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $15k of CTSO on Sep 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Alan D. Sobel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alan D. Sobel has 0.
Where does Alan D. Sobel file Form 4?
Alan D. Sobel has filed Form 4 at CTSO (Cytosorbents Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.